Literature DB >> 12878540

Dinucleotide analogues as novel inhibitors of RNA-dependent RNA polymerase of hepatitis C Virus.

Weidong Zhong1, Haoyun An, Dinesh Barawkar, Zhi Hong.   

Abstract

Replication of hepatitis C virus (HCV) RNA is catalyzed by the virally encoded RNA-dependent RNA polymerase NS5B. It is believed that the viral polymerase utilizes a de novo or primer-independent mechanism for initiation of RNA synthesis. Our previous work has shown that dinucleotides were efficient initiation molecules for NS5B in vitro (W. Zhong, E. Ferrari, C. A. Lesburg, D. Maag, S. K. Ghosh, C. E. Cameron, J. Y. Lau, and Z. Hong, J. Virol. 74:9134-9143, 2000). In this study, we further demonstrated that dinucleotide analogues could serve as inhibitors of de novo initiation of RNA synthesis directed by HCV NS5B. Both mononucleotide- and dinucleotide-initiated RNA syntheses were affected by dinucleotide analogues. The presence of the 5'-phosphate group in the dinucleotide compounds was required for efficient inhibition of de novo initiation. Optimal inhibitory activity also appeared to be dependent on the base-pairing potential between the compounds and the template terminal bases. Because the initiation process is a rate-limiting step in viral RNA replication, inhibitors that interfere with the initiation process will have advantages in suppressing virus replication. The use of dinucleotide analogues as inhibitor molecules to target viral replication initiation represents a novel approach to antiviral interference.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12878540      PMCID: PMC166071          DOI: 10.1128/AAC.47.8.2674-2681.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Natural history of hepatitis C.

Authors:  L B Seeff
Journal:  Am J Med       Date:  1999-12-27       Impact factor: 4.965

2.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

Review 3.  Treatment of hepatitis C: impact on the virus, quality of life and the natural history.

Authors:  P Michielsen; R Brenard; H Reynaert
Journal:  Acta Gastroenterol Belg       Date:  2002 Apr-Jun       Impact factor: 1.316

4.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

5.  A recombinant hepatitis C virus RNA-dependent RNA polymerase capable of copying the full-length viral RNA.

Authors:  J W Oh; T Ito; M M Lai
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

6.  De novo RNA synthesis catalyzed by HCV RNA-dependent RNA polymerase.

Authors:  X L Sun; R B Johnson; M A Hockman; Q M Wang
Journal:  Biochem Biophys Res Commun       Date:  2000-02-24       Impact factor: 3.575

7.  De novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virus.

Authors:  G Luo; R K Hamatake; D M Mathis; J Racela; K L Rigat; J Lemm; R J Colonno
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

8.  Template requirement and initiation site selection by hepatitis C virus polymerase on a minimal viral RNA template.

Authors:  J W Oh; G T Sheu; M M Lai
Journal:  J Biol Chem       Date:  2000-06-09       Impact factor: 5.157

9.  Template/primer requirements and single nucleotide incorporation by hepatitis C virus nonstructural protein 5B polymerase.

Authors:  W Zhong; E Ferrari; C A Lesburg; D Maag; S K Ghosh; C E Cameron; J Y Lau; Z Hong
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

10.  A novel mechanism to ensure terminal initiation by hepatitis C virus NS5B polymerase.

Authors:  Z Hong; C E Cameron; M P Walker; C Castro; N Yao; J Y Lau; W Zhong
Journal:  Virology       Date:  2001-06-20       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.